dc.contributor.author | Muhammad, Zeeshan | |
dc.contributor.author | Skagseth, Susann | |
dc.contributor.author | Boomgaren, Marc | |
dc.contributor.author | Akhter, Sundus | |
dc.contributor.author | Frøhlich, Christopher | |
dc.contributor.author | Ismael, Aya | |
dc.contributor.author | Christopeit, Tony | |
dc.contributor.author | Bayer, Annette | |
dc.contributor.author | Leiros, Hanna-Kirsti S. | |
dc.date.accessioned | 2020-07-08T12:25:06Z | |
dc.date.available | 2020-07-08T12:25:06Z | |
dc.date.issued | 2020-06-18 | |
dc.description.abstract | Metallo-β-lactamases (MBLs) are an emerging cause of bacterial antibiotic resistance by hydrolysing all classes of β-lactams except monobactams, and the MBLs are not inhibited by clinically available serine-β-lactamase inhibitors. Two of the most commonly encountered MBLs in clinical isolates worldwide – the New Delhi metallo-β-lactamase (NDM-1) and the Verona integron-encoded metallo-β-lactamase (VIM-2) – are included in this study.<p>
A series of several <i>N</i>H-1,2,3-triazoles was prepared by a three-step protocol utilizing Banert cascade reaction as the key step. The inhibitor properties were evaluated in biochemical assays against the MBLs VIM-2, NDM-1 and GIM-1, and VIM-2 showed IC<sub>50</sub> values down to nanomolar range. High-resolution crystal structures of four inhibitors in complex with VIM-2 revealed hydrogen bonds from the triazole inhibitors to Arg228 and to the backbone of Ala231 or Asn233, along with hydrophobic interactions to Trp87, Phe61 and Tyr67. The inhibitors show reduced MIC in synergy assays with <i>Pseudomonas aeruginosa</i> and <i>Escherichia coli</i> strains harbouring VIM enzymes. The obtained results will be useful for further structural guided design of MBL inhibitors. | en_US |
dc.identifier.citation | Muhammad M, Skagseth S, Boomgaren M, Akhter S, Frøhlich CF, Ismael A, Christopeit T, Bayer A, Leiros H. Structural studies of triazole inhibitors with promising inhibitor effects against antibiotic resistance metallo-β-lactamases. Bioorganic & Medicinal Chemistry. 2020:115598 | en_US |
dc.identifier.cristinID | FRIDAID 1816421 | |
dc.identifier.issn | 0968-0896 | |
dc.identifier.issn | 1464-3391 | |
dc.identifier.uri | https://hdl.handle.net/10037/18778 | |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.journal | Bioorganic & Medicinal Chemistry | |
dc.relation.projectID | info:eu-repo/grantAgreement/RCN/SYNKNØYT/218539/Norway/High Throughput Pipeline for Structure Based Drug Design, and Antibiotic Resistance Enzymes in particular// | en_US |
dc.relation.projectID | info:eu-repo/grantAgreement/RCN/FRIMEDBIO/213808/Norway/Combating Antibiotic Resistance - Development of Inhibitors against Antibiotic Resistance Enzymes// | en_US |
dc.relation.projectID | info:eu-repo/grantAgreement/RCN/BEDREHELSE/273332/Norway/Inhibition of clinically relevant carbapenemases/ICARBA/ | en_US |
dc.rights.accessRights | openAccess | en_US |
dc.rights.holder | Copyright 2020 The Author(s) | en_US |
dc.subject | VDP::Mathematics and natural science: 400::Chemistry: 440 | en_US |
dc.subject | VDP::Matematikk og Naturvitenskap: 400::Kjemi: 440 | en_US |
dc.title | Structural studies of triazole inhibitors with promising inhibitor effects against antibiotic resistance metallo-β-lactamases | en_US |
dc.type.version | publishedVersion | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |